Johannes Brägelmann

Excited to share our paper on AI-based prediction of disease progression in squamous skin cancers in @Nature_NPJ! Great collaboration w Juan Pisula & @bozeklab using federated learning & explainable AI for high accuracy while preserving patient privacy: nature.com/articles/s4169…

🚨 New preprint drop! MOSAIC builds a pan-cancer spatial + single-cell multi-omics atlas of thousands of tumors, exposing the fine-grained mosaic of intra-tumoral heterogeneity and immune niches. A game-changer for #PrecisionOncology and data-hungry AI models. More to come (much…

Online Now: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma dlvr.it/TLQ4ty

ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2). 👉#bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). 👆Encouraging tolerability @MattGalsky @nachoduranm @AndreaNecchi

Significant data from @niklas_kluemper and team on Zelenectide in heavily pretreated breast cancer patients with Nectin-4 amplification showing an ORR of 57.1% @Bicycle_tx

Happy to share our poster #SABCS24 @SABCSSanAntonio: In heavily pretreated breast cancer from the Phase 1/2 Duravelo-1 trial, pts with NECTIN4 amplification had a 57.1% ORR with zelenectide pevedotin (Zele, formerly BT8009) vs. ~6.3% in non-amp. Notably, responses were seen even…

Now online in @CD_AACR: Sympathetic Neurons Promote Small Cell Lung Cancer Through the β2 Adrenergic Receptor - by Tala, @JianwenQue, and colleagues @ColumbiaMed @columbiacancer doi.org/10.1158/2159-8… #CancerNeuroscience #SCLC

😱 Don't get spooked by new data - watch the #UromigosLive24 panel on novel ADCs in urothelial carcinoma discussed by @tompowles1, @apolo_andrea, @PGrivasMDPhD, @shilpaonc, and @kalasri3. 🔬 Learn about a new study from Dr. Yohann Loriot of @GustaveRoussy on BT8009, HER3, and…

Cologne Conference on Lung Cancer June 26-27, 2025 On behalf of the conference chair Caroline Dive and the organizing committee Reinhard Buettner, Roman Thomas, Juergen Wolf we are pleased to share news about the next CCLC #CCLC #Networking #Conference2025 #lungcancer #cologne

Next-generation lung cancer pathology: Development and validation of diagnostic and prognostic algorithms out on @CellCellPress Study presents a computational🖥️🔬 pathology platform for non-small cell #LungCancer 🫁 #NSCLC ) that aids in patient care optimization and…

Very happy to share our letter published @EUplatinum ➡️Membranous expression of target protein is required for ADC response in urothelial cancer sciencedirect.com/science/articl… Thanks to the great co-authors @Markuseckstein3 @KuppeChristoph @braegelmannlab @ViktorGruenwald…

Happy to share our novel manuscript on "Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer" ➡️efficacy of ADC for active cerebral metastases has been demonstrated already…

Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn nej.md/3Ku4X0H

New hypothesis from our lab! Explore the age-related decline of helicase function and its impact on genome instability. Discover how G-quadruplex structures might drive DNA damage in aging. 🧬 #Aging #Sirtuins #Helicases #Gquadruplex #Rloops 🔗 Read more: febs.onlinelibrary.wiley.com/doi/epdf/10.10…

FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer bit.ly/3UUj04v

Very exciting! ASCO abstracts on phase EV-202 results have just been released: Anti-NECTIN4 Enfortumab vedotin with disappointing efficacy in biomarker-unselected population beyond UC @ASCO #ASCO24 Confirmed ORR in - esophageal cancer 18.2% - gastric cancer 9.5% - NSCLC:…

🔬Join our Department! Apply now for this PostDoc opportunity in cancer genetics, cancer cell biology and cancer immunology. 👩‍🔬🧑‍🔬 @sfb1399 @DTG_Cologne jobs-uk-koeln.de/index.php?ac=j…

A lot about anti-NECTIN4 ADC Enfortumab vedotin (EV) beyond UC at #ASCO24! @ASCO Data of multi-cohort EV-202 (NCT04225117) will be released! ➡️Excited to see the single-agent activity of EV in biomarker-unselected (NECTIN4 status not required!) - gastric/esophageal cancer…

Congrats 🥳

Great review about current developments and future directions for ADCs for NSCLC and breast cancer! @Annals_Oncology @etop_ibcsg @FAndreMD 100% agreement with their statements for met. UC too! ➡️As the number of available ADCs increases (NECTIN4, Trop2, Her2..), biomarkers are…